







# CAT-1004, an Oral Agent Targeting Activated NF-κB in Development as a Disease-Modifying Treatment for Treatment for Duchenne Muscular Dystrophy: Design of MoveDMD, a Phase 1 / 2 Trial

JM Donovan<sup>1</sup>, HL Sweeney<sup>2</sup>, K Vandenborne<sup>3</sup>, BS Russman<sup>4</sup>, M Jirousek<sup>1</sup>, RS Finkel<sup>5</sup>  
<sup>1</sup>Catabasis Pharmaceuticals, <sup>2</sup>U of Pennsylvania Perelman School of Medicine, <sup>3</sup>U of Florida, <sup>4</sup>Oregon Health & Science University, <sup>5</sup>Nemours Children's Hospital



## Background



## MoveDMD Study Design

